Drug intelligence / Profile preview

ZL-49

Development stage: Preclinical
Lead developer: Zenitar
Modality: Small Molecules

Overview

ZL-49 is a small-molecule inhibitor of Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2), currently under development by Chengdu Zenitar Biomedical Technology. RIPK2 is a critical signaling protein that mediates the inflammatory response triggered by the activation of NOD1 and NOD2 receptors. By blocking RIPK2 activity, ZL-49 aims to reduce the production of pro-inflammatory cytokines, providing a targeted therapeutic approach for the treatment of Ulcerative Colitis (UC) and other inflammatory disorders.

Targets

RIPK2 (Receptor-interacting protein serine/threonine kinase 2)

Beyond the preview

Go deeper on ZL-49.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZL-49.

Explore the full profile